Richard Francis Intended to be Appointed Purespring Therapeutics CEO Following Completion of Its Series A Financing of £45.0 Mil, from 1 February 2021
Richard is a leading pharmaceutical executive with over 25 years’ experience in building sustainable, world-class life science companies. He most recently held the role of Chief Executive Officer of Sandoz, a division of Novartis. Sandoz is a global leader in generic pharmaceuticals and biosimilars.

